By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Celyad (Formally Known as Cardio3 BioSciences) 

Parc de L’Alliance
9, Boulevard de France
Braine - L’Alleud    1420  Belgium
Phone: 32-2-790-35-30 Fax: 32-2-790-35-35



Company News
Celyad Reports 2016 Financial And Operating Results And Expected Key Milestones For 2017 3/23/2017 10:13:25 AM
USPTO Rejects New Reexamination Request Against Celyad’s US Patent For Production Of Allogeneic TCR-Deficient CAR-T Cells 3/16/2017 7:46:03 AM
Celyad Obtains FDA Approval To Initiate The NKR-2 CAR T Cells THINK Trial In The U.S. 3/8/2017 10:23:16 AM
Celyad Registers First Hematological Patient In CAR-T NKR-2 THINK Trial 2/16/2017 9:11:00 AM
Celyad Announces USPTO Decision To Uphold U.S. Patent For Production Of Allogeneic TCR-Deficient CAR-T Cells 1/9/2017 7:22:03 AM
Celyad Release: Biotech Announces Registration Of The First Pancreatic Cancer Patient In Its CAR-T NKR-2THINK Trial In Belgium 12/14/2016 2:20:23 PM
Celyad's CAR-T Candidate Delivers in Early Stage Study 11/7/2016 5:56:36 AM
Celyad CEO Accuses Cellectis (ALCLS)' Leader of Lying About CAR-T Patent 11/4/2016 5:46:37 AM
Celyad Successfully Completes Safety Follow-Up Of The First Patient At The Fourth Dose Level In The NKR-2 Phase I Trial 7/14/2016 9:39:45 AM
Celyad Hammers Out NKR-2 T-cell Immunotherapy Deal Worth $311.5 Million with Ono Pharma 7/11/2016 6:06:18 AM